Shen 2015.

Methods	Study design: Randomised clinical trial Study duration: January 2012 to November 2013 Duration of follow‐up: 2 years Setting: Hospital
Participants	Age (mean ± SD, range): 40.23 ± 8.23 years, 32‐59 years Male (n/total): 66/96 Tumour diameter (mean ± SD, range): 6.23 ± 2.45 cm, 2.5‐11.4 cm Child‐Pugh Class (patients): Child‐A 50, Child‐B 40, Child‐C 6
Interventions	TACE + RFA group (n = 48): TACE: TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation RFA: The interval between TACE and RFA was 2‐4 weeks. In total of 20‐30 minutes TACE group (n = 48): TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation
Outcomes	Tumour response, according to RECIST criteria, measured at 6 months 1‐ and 2‐ year survival rates Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.